SanBio CoSNBIF 22 PB Ratio is 16.11 as of Jul. 11, 2026, which is 56% above its 10-year median of 10.34. GuruFocus rates SNBIF with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 1,227 Biotechnology companies, SanBio Co ranks worse than 74.49% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-11), SanBio Co's share price is $16.45. SanBio Co's Book Value per Share for the quarter that ended in Jan. 2026 was $1.02. Hence, SanBio Co's PB Ratio of today is 16.11.
The historical rank and industry rank for SanBio Co's PB Ratio or its related term are showing as below:
SNBIF'
s PB Ratio Range Over the Past 10 Years
Min: 2.42 Med: 10.34 Max: 222.06
Current: 6.61
During the past 13 years, SanBio Co's highest PB Ratio was 222.06. The lowest was 2.42. And the median was 10.34.
SNBIF's PB Ratio is ranked worse than 74.49% of 1227
companies
in the Biotechnology industry
Industry Median: 2.95
vs SNBIF: 6.61
During the past 12 months, SanBio Co's average Book Value Per Share Growth Rate was 601.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 36.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -4.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -5.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of SanBio Co was 104.90% per year. The lowest was -39.70% per year. And the median was -3.15% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
SanBio Co PB Ratio Related Terms
SanBio Co PB Ratio Historical Data
* Premium members only.
The historical data trend for SanBio Co's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SanBio Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SanBio Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SanBio Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where SanBio Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
SanBio Co's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
SanBio Co (SNBIF) has a PB Ratio of 16.11 as of Jul. 11, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on SanBio Co and its competitors. This is 56% above median its historical median of 10.34. Over the past decade, SanBio Co's PB Ratio has ranged from 2.42 to 222.06. According to the industry distribution chart, SanBio Co ranks #914 out of 1227 companies in the Biotechnology industry, placing it in the top 74.5%.
Is SanBio Co's PB Ratio too high?
SanBio Co's current PB Ratio of 16.11 is 56% above median its 10-year median of 10.34. Over the past 10 years, this metric has ranged from a low of 2.42 to a high of 222.06. The Biotechnology industry median PB Ratio is 2.95. SanBio Co's value of 16.11 is 446.1% above this industry median. Based on the distribution chart, SanBio Co ranks #914 out of 1227 companies in the Biotechnology industry, which is below the industry midpoint. Overall, SanBio Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does SanBio Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SanBio Co ranks #914 out of 1227 companies for PB Ratio. This places SanBio Co in the lower half of its industry. The industry median PB Ratio is 2.95. SanBio Co's value of 16.11 is 446.1% above this benchmark. Historically, SanBio Co's own PB Ratio has ranged from 2.42 to 222.06 over the past decade. While the company's 10-year median is 10.34 vs. the industry median of 2.95, SanBio Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SanBio Co's current PB Ratio of 16.11 is 446.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on SanBio Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SanBio Co's current PB Ratio is 16.11, which is 56% above median its own 10-year median of 10.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SanBio Co stock overvalued right now?
SanBio Co (SNBIF) has a current PB Ratio of 16.11. The current PB Ratio is 16.11, which is 56% above median its 10-year median of 10.34 and 446.1% above the Biotechnology industry median of 2.95. SanBio Co's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For SanBio Co (SNBIF), the current PB Ratio is 16.11 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.
22GF Score
Get the complete analysis for SNBIF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNBIF has been successfully added to your 
